Galmed Pharmaceuticals Regains Nasdaq Compliance

Galmed Pharmaceuticals (GLMD) has released an update.

Galmed Pharmaceuticals Ltd. has successfully regained compliance with Nasdaq’s minimum bid price requirement, ensuring its ordinary shares will remain listed on the Nasdaq Stock Market. The company had previously been warned about its stock price falling below $1.00 but managed to maintain a closing bid price above this threshold for the necessary 10 consecutive trading days. This achievement secures the company’s continued presence in the marketplace, offering stability to its investors.

For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.